Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole plus metronomic capecitabine versus capecitabine in advanced gastrointestinal tumors
2013-001096-20Phase 2Active
- Sponsor
- Department of Molecular and Clinical Medicine; "Sapienza" University of Rome
- Start
- Jan 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastrointestinal cancer comparing Capecitabine monotherapy with Rabeprazole + capecitabine (2 arms). Primary endpoint: 3-month progression-free survival. Started Jan 2014; status: active.
02
Drugs
rabeprazolecapecitabine
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on 2013-001096-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001096-20.